GARAKANI: Department of Psychiatry and Behavioral Health, Greenwich Hospital, Greenwich, CT; Department of Psychiatry, Yale University School of Medicine, New Haven, CT

ALEXANDER: Private Practice, Berkeley, CA

SUMNER: Department of Psychiatry, Charles E. Schmidt College of Medicine of Florida Atlantic University, Boca Raton, FL

PINE and GROSS: Department of Psychiatry, Keck School of Medicine of University of Southern California, Los Angeles, CA

RAISON: Department of Human Development and Family Studies, School of Human Ecology, University of Wisconsin-Madison, Madison, WI, and Department of Psychiatry, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI

AARONSON: Institute for Advanced Therapeutics and Diagnostics, Sheppard Pratt, Towson, MD, and University of Maryland School of Medicine, Department of Psychiatry, Baltimore, MD

BARON: Western University of Health Sciences, Pomona, CA, and Department of Psychiatry, Keck School of Medicine of University of Southern California, Los Angeles, CA

Dr. C.L.R. serves as a consultant for Usona Institute, Novartis, Sage/Biogen, and Emory Healthcare. Dr. S.T.A. has received research support from Compass Pathways and Neuronetics. He serves as a consultant to Compass Pathways, Neuronetics, LivaNova, Sage Therapeutics, and Genomind. The remaining authors declare no conflicts of interest.

Please send correspondence to: Amir Garakani, MD, Chair, Department of Psychiatry and Behavioral Health, Greenwich Hospital, 5 Perryridge Road, Greenwich, CT 06830 (e-mail: [email protected]).